Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers identified novel antibody fragments targeting oncofetal chondroitin sulfate (ofCS), an embryonic signature found in tumors. These fragments show promise for developing new cancer therapies and diagnostics.
Area Of Science
- Oncology
- Immunology
- Biotechnology
Background
- Malignant cells share molecular similarities with embryonic cells, presenting unique therapeutic targets.
- Oncofetal chondroitin sulfate (ofCS) is an embryonic marker expressed by tumors, promoting cancer progression and metastasis.
Purpose Of The Study
- To identify and characterize antibody fragments that specifically target oncofetal chondroitin sulfate (ofCS).
- To evaluate the therapeutic and diagnostic potential of these anti-ofCS antibody fragments in various cancer models.
Main Methods
- Phage display technology was used to discover antibody fragments targeting distinct ofCS epitopes.
- Binding affinity and specificity were assessed in vitro and in vivo across diverse solid tumor types.
- Anti-ofCS antibody drug conjugates and bispecific immune cell engagers were constructed and tested.
Main Results
- Novel antibody fragments demonstrated high binding affinity (low nanomolar range) to ofCS.
- These fragments exhibited specific binding to solid tumors, with minimal interaction with healthy or benign tissues.
- Therapeutic conjugates and engagers effectively disrupted tumor progression in preclinical cancer models.
Conclusions
- Anti-ofCS antibody fragments represent promising tools for targeted cancer therapy and diagnostics.
- These findings support the development of broadly effective treatments for human malignancies based on ofCS targeting.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...